Companies: 10,795·Total market cap: $144.5T
Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

RYTMNASDAQHealthcare● Active
$86.73
+$0.33(+0.38%)
Market Cap$5.9B
P/E Ratio
52W High$122.2
52W Low$60.7
SEC Filings

Rhythm Pharmaceuticals, Inc. (RYTM) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001649904 · RYTM · NASDAQ · as of Jun 8, 2026

Filing snapshot

806
Total Filings
DEFA14A
Latest Form
2026-05-29
Most Recent
2017
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001649904 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001628280-26-012399
Primary Document
rytm-20251231.htm
Source: data.sec.gov · CIK 0001649904 · Accession 0001628280-26-012399

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-05
8-KCurrent Report
8-K
2026-05-05Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-29
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
S-8Employee Stock Plan Registration
S-8
2026-05-05
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-05
View
10-QQuarterly Report
10-Q
2026-05-05
View
8-KCurrent Report
8-K
2026-05-05
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-30
View
ARSARS
ARS
2026-04-29
View
DEF 14AProxy Statement
DEF 14A
2026-04-29
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-03
View
8-KCurrent Report
8-K
2026-04-03
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-27
View
8-KCurrent Report
8-K
2026-03-26
View
8-KCurrent Report
8-K
2026-03-20
View
8-KCurrent Report
8-K
2026-03-16
View
Showing 1–15 of 372 filingsForm 4 / 144 hidden· 806 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001649904  |  Exchange: NASDAQ · Healthcare

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) has submitted 806 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2017. As a Healthcare sector company with CIK 0001649904, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Rhythm Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Rhythm Pharmaceuticals, Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical RYTM 10-K annual reports are available from 2015 through 2026.

Investors researching Rhythm Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

RYTM SEC Filings · 8 questions

Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 806 filings and access original documents at no cost. Rhythm Pharmaceuticals, Inc.'s CIK is 0001649904.

RYTM SEC filingsRhythm Pharmaceuticals, Inc. SEC documentsfind RYTM 10-K